Walleye Capital LLC Glycomimetics Inc Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $119,091 - $193,960	-38,792 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $296,184 - $540,609	-143,779 Reduced 78.75%	38,792 $146,000
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $310,662 - $918,407	169,761 Added 1325.22%	182,571 $417,000
Q4 2019 Feb 14, 2020	SELL	$4.03 - $6.5 $73,305 - $118,235	-18,190 Reduced 58.68%	12,810 $67,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $86,800 - $398,350	31,000 New	31,000 $134,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $20.4M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.